| |
Internet proxy voting allows you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.
|
| |
Name
|
| |
Class
|
| |
Age
|
| |
Position
|
| |
Director
Since |
|
John A. Orwin | | |
III
|
| |
56
|
| |
President, Chief Executive Officer and Director
|
| |
2018
|
|
Tito A. Serafini, Ph.D. | | |
II
|
| |
57
|
| | Chief Strategy Officer and Director | | |
2010
|
|
Brian Atwood | | |
II
|
| |
68
|
| | Director | | |
2013
|
|
Kristine M. Ball | | |
III
|
| |
49
|
| | Director | | |
2020
|
|
Franklin Berger | | |
III
|
| |
71
|
| | Director | | |
2014
|
|
David Lacey, M.D. | | |
I
|
| |
68
|
| | Director | | |
2016
|
|
William H. Robinson, M.D. Ph.D. | | |
II
|
| |
53
|
| | Director | | |
2011
|
|
Lindsey Rolfe, MBChB | | |
I
|
| |
53
|
| | Director | | |
2019
|
|
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating
and Corporate Governance |
| |
Research
and Development Committee |
| ||||||||||||
John A. Orwin
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Tito A. Serafini, Ph.D.
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Brian Atwood
|
| | | | X | | | | | | X* | | | | | | | | | | | | | | |
Kristine M. Ball
|
| | | | X | | | | | | | | | | | | X | | | | | | | | |
Franklin Berger
|
| | | | X* | | | | | | | | | | | | X | | | | | | | | |
David Lacey, M.D.
|
| | | | | | | | | | X | | | | | | X* | | | | | | X | | |
William H. Robinson, M.D., Ph.D.
|
| | | | | | | | | | | | | | | | | | | | | | X* | | |
Lindsey Rolfe, MBChB
|
| | | | | | | | | | X | | | | | | | | | | | | X | | |
Total meetings in 2020
|
| | | | 4 | | | | | | 6 | | | | | | 3 | | | | | | 5 | | |
Name
|
| |
Fees Earned
or Paid in Cash ($) |
| |
Option
Awards ($)(1)(3) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||
Brian Atwood
|
| | | $ | 87,500 | | | | | $ | 152,690 | | | | | $ | — | | | | | $ | 240,190 | | |
Kristine M. Ball
|
| | | $ | 28,488 | | | | | $ | 470,526 | | | | | $ | — | | | | | $ | 499,014 | | |
Franklin Berger
|
| | | $ | 54,000 | | | | | $ | 152,690 | | | | | $ | — | | | | | $ | 206,690 | | |
David Lacey, M.D.
|
| | | $ | 52,643 | | | | | $ | 152,690 | | | | | $ | — | | | | | $ | 205,333 | | |
William H. Robinson, M.D. Ph.D.(2)
|
| | | $ | 47,191 | | | | | $ | 152,690 | | | | | $ | 250,000 | | | | | $ | 449,881 | | |
Lindsey Rolfe, MBChB
|
| | | $ | 45,643 | | | | | $ | 152,690 | | | | | $ | — | | | | | $ | 198,333 | | |
Name
|
| |
Number of
shares subject to outstanding options as of December 31, 2020 |
| |||
Brian Atwood
|
| | | | 58,666 | | |
Kristine M. Ball
|
| | | | 36,000 | | |
Franklin Berger
|
| | | | 46,166 | | |
David Lacey, M.D.
|
| | | | 66,532 | | |
William H. Robinson, M.D. Ph.D.
|
| | | | 73,666 | | |
Lindsey Rolfe, MBChB
|
| | | | 36,000 | | |
| | |
Fiscal Year Ended
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Audit Fees(1)
|
| | | $ | 604,876 | | | | | $ | 556,626 | | |
Audit-Related Fees(2)
|
| | | | — | | | | | | 7,926 | | |
Tax Fees
|
| | | | — | | | | | | — | | |
All Other Fees
|
| | | | — | | | | | | — | | |
Total Fees
|
| | | $ | 604,876 | | | | | $ | 564,522 | | |
| | |
Number of Beneficially
Owned Shares(1) |
| |
Percentage of Shares
Beneficially Owned |
| ||||||||||||||||||
Beneficial Owner
|
| |
Class A
Common Stock |
| |
Class B
Common Stock |
| |
Class A
Common Stock |
| |
Class B
Common Stock |
| ||||||||||||
5% Stockholders | | | | | | | | | | | | | | | | | | | | | | | | | |
Entities Affiliated with Baker Brothers Life Sciences, L.P.(2)
|
| | | | 3,532,760 | | | | | | 6,715,441 | | | | | | 11.74% | | | | | | 100% | | |
Entities Affiliated with Boxer Capital, LLC(3)
|
| | | | 2,202,333 | | | | | | — | | | | | | 7.32% | | | | | | — | | |
Waveform & Co.(4)
|
| | | | 3,357,984 | | | | | | | | | | | | 11.16% | | | | | | | | |
BlackRock, Inc.(5)
|
| | | | 2,724,211 | | | | | | — | | | | | | 9.05% | | | | | | — | | |
EcoR1 Capital LLC(6)
|
| | | | 2,426,685 | | | | | | — | | | | | | 8.06% | | | | | | — | | |
Redmile Group LLC(7)
|
| | | | 2,476,068 | | | | | | — | | | | | | 8.23% | | | | | | — | | |
Directors and Named Executive Officers | | | | | | | | | | | | | | | | | | | | | | | | | |
John A. Orwin(8)
|
| | | | 920,781 | | | | | | — | | | | | | 2.97% | | | | | | — | | |
Tito A. Serafini, Ph.D.(9)
|
| | | | 616,974 | | | | | | — | | | | | | 2.03% | | | | | | — | | |
Brian Atwood(10)
|
| | | | 77,818 | | | | | | — | | | | | | * | | | | | | — | | |
Kristine M. Ball
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Franklin Berger(11)
|
| | | | 113,472 | | | | | | — | | | | | | * | | | | | | — | | |
David Lacey, M.D.(12)
|
| | | | 36,030 | | | | | | — | | | | | | * | | | | | | — | | |
William Robinson, M.D., Ph.D.(13)
|
| | | | 416,250 | | | | | | — | | | | | | 2.13% | | | | | | — | | |
Lindsey Rolfe, MBChB
|
| | | | 8,000 | | | | | | — | | | | | | * | | | | | | — | | |
Herbert Cross(14)
|
| | | | 153,437 | | | | | | — | | | | | | * | | | | | | — | | |
Norman Michael Greenberg, Ph.D. (15)
|
| | | | 102,457 | | | | | | — | | | | | | * | | | | | | — | | |
All executive officers and directors as a group (11 persons)(16)
|
| | | | 2,530,322 | | | | | | — | | | | | | 7.68% | | | | | | — | | |
Name
|
| |
Age
|
| |
Current Position(s) with Atreca, Inc.
|
|
John A. Orwin | | |
56
|
| | President, Chief Executive Officer and Director | |
Herbert Cross | | |
49
|
| | Chief Financial Officer | |
Tito A. Serafini, Ph.D. | | |
57
|
| | Chief Strategy Officer and Director | |
Courtney J. Phillips | | |
46
|
| | General Counsel and Corporate Secretary | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Option
Awards ($)(1) |
| |
Non-Equity
Incentive Plan Compensation ($)(2) |
| |
All Other
Compensation ($)(3) |
| |
Total
($) |
| ||||||||||||||||||
John A. Orwin
President and Chief Executive Officer |
| | | | 2020 | | | | | | 566,500 | | | | | | 3,776,010 | | | | | | 295,996 | | | | | | 1,020 | | | | | | 4,639,526 | | |
| | | 2019 | | | | | | 507,027 | | | | | | — | | | | | | 332,750 | | | | | | 5,362 | | | | | | 845,139 | | | ||
Norman Michael Greenberg, Ph.D(4)
Former Chief Scientific Officer |
| | | | 2020 | | | | | | 425,390 | | | | | | 1,378,568 | | | | | | 161,648 | | | | | | 99,619 | | | | | | 2,065,224 | | |
| | | 2019 | | | | | | 411,352 | | | | | | 423,790 | | | | | | 165,200 | | | | | | 106,916 | | | | | | 1,107,258 | | | ||
Herbert Cross
Chief Financial Officer |
| | | | 2020 | | | | | | 405,600 | | | | | | 1,519,827 | | | | | | 184,954 | | | | | | 1,020 | | | | | | 2,111,401 | | |
| | | 2019 | | | | | | 312,722 | | | | | | 2,283,292 | | | | | | 187,200 | | | | | | 1,794 | | | | | | 2,785,008 | | |
| | | | | | | | |
Option Awards
|
| |||||||||||||||||||||
| | | | | | | | |
Number of securities underlying
unexercised options |
| |
Option
exercise price |
| |
Option
expiration date |
| |||||||||||||||
Name
|
| |
Grant Date
|
| |
(#) exercisable
|
| |
(#) unexercisable
|
| |
($)
|
| ||||||||||||||||||
John A. Orwin
|
| | | | 4/28/2018(1) | | | | | | 695,832 | | | | | | — | | | | | $ | 5.16 | | | | | | 4/27/2028 | | |
| | | | | 10/30/2018(2) | | | | | | 80,576 | | | | | | 68,178 | | | | | $ | 10.02 | | | | | | 10/29/2028 | | |
| | | | | 11/15/2018(2) | | | | | | 30,728 | | | | | | 28,267 | | | | | $ | 10.02 | | | | | | 11/14/2028 | | |
| | | | | 2/26/20(2) | | | | | | 55,229 | | | | | | 185,771 | | | | | $ | 22.07 | | | | | | 2/25/2030 | | |
Norman Michael Greenberg, Ph.D.
|
| | | | 5/10/2016(1) | | | | | | 11,929 | | | | | | — | | | | | $ | 4.56 | | | | | | 5/9/2026 | | |
| | | | | 4/28/2018(3) | | | | | | 44,999 | | | | | | — | | | | | $ | 5.16 | | | | | | 4/27/2028 | | |
| | | | | 1/31/2019(2) | | | | | | 22,924 | | | | | | 27,075 | | | | | $ | 12.06 | | | | | | 1/30/2029 | | |
| | | | | 2/26/2020(2) | | | | | | 20,166 | | | | | | 67,834 | | | | | $ | 22.07 | | | | | | 2/25/2030 | | |
Herbert Cross
|
| | | | 4/5/2019(4) | | | | | | 103,125 | | | | | | 121,874 | | | | | $ | 12.06 | | | | | | 4/4/2029 | | |
| | | | | 2/26/2020(2) | | | | | | 22,229 | | | | | | 74,771 | | | | | $ | 22.07 | | | | | | 2/25/2030 | | |
Plan Category(1)
|
| |
Number of securities
to be issued upon exercise of outstanding options, warrants and rights (a) |
| |
Weighted-average
exercise price of outstanding options, warrants and rights (b) |
| |
Number of securities
remaining available for issuance under equity compensation plans (excluding securities reflected in column (a))(c) |
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 4,862,220(2) | | | | | $ | 13.34 | | | | | | 2,563,706(3)(4)(5) | | |